About: Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The ability of a nucleotide analogue PMEG to induce resistance and the mechanisms involved were adressed. CCRF-CEM cells resistant to either PMEG or its congener PMEDAP were assayed for the expression of membrane transporters, PMEG and PMEDAP uptake and metabolism. PMEG phosphorylation to PMEG mono- and diphosphate was completely impaired in resistant cells. Guanylate kinase (GUK) obtained from PMEG-resistant cells revealed two point mutations S(35)N V(168)F that significantly suppressed its catalytic activity. Transfection with wtGUK led to the recovery of phosphorylating activity and sensitivity towards PMEG cytotoxicity. Primary sequence of adenylate kinase (AK) from PMEDAP resistant cells was unaffected. Resistance induced by PMEDAP is thus conferred by other mechanisms. No differences in PMEG uptake have been found between sensitive and resistant cells. GUK was identified as the sole molecular target for the development of resistance to PMEG. The ability of a nucleotide analogue PMEG to induce resistance and the mechanisms involved were adressed. CCRF-CEM cells resistant to either PMEG or its congener PMEDAP were assayed for the expression of membrane transporters, PMEG and PMEDAP uptake and metabolism. PMEG phosphorylation to PMEG mono- and diphosphate was completely impaired in resistant cells. Guanylate kinase (GUK) obtained from PMEG-resistant cells revealed two point mutations S(35)N V(168)F that significantly suppressed its catalytic activity. Transfection with wtGUK led to the recovery of phosphorylating activity and sensitivity towards PMEG cytotoxicity. Primary sequence of adenylate kinase (AK) from PMEDAP resistant cells was unaffected. Resistance induced by PMEDAP is thus conferred by other mechanisms. No differences in PMEG uptake have been found between sensitive and resistant cells. GUK was identified as the sole molecular target for the development of resistance to PMEG. (en)
Title	Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG (en)
skos:prefLabel	Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG (en)
skos:notation	RIV/61388963:_____/11:00360711!RIV12-AV0-61388963
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(1M0508), Z(AV0Z40550506)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Votruba, Ivan Holý, Antonín Mertlíková-Kaiserová, Helena Procházková, Eliška Tloušťová, Eva Rumlová, Michaela
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav organické chemie a biochemie AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	220965
http://linked.open...ai/riv/idVysledku	RIV/61388963:_____/11:00360711
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	resistance; acyclic nucleoside phosphonates; PMEG; PMEDAP (en)
http://linked.open.../riv/klicoveSlovo	resistance acyclic nucleoside phosphonates PMEDAP PMEG
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[986D0C17453C]
http://linked.open...i/riv/nazevZdroje	Biochemical Pharmacology
http://linked.open...in/vavai/riv/obor	CE
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	6 (xsd:int)
http://linked.open...vavai/riv/projekt	New Antivirals and Antineoplastics
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	82
http://linked.open...iv/tvurceVysledku	Holý, Antonín Mertlíková-Kaiserová, Helena Votruba, Ivan Procházková, Eliška Rumlová, Michaela Tloušťová, Eva
http://linked.open...ain/vavai/riv/wos	000291760700005
http://linked.open...n/vavai/riv/zamer	Regulace biologických procesů: Chemické modulátory vybraných systémů významných pro medicínu a zemědělství
issn	0006-2952
number of pages	8 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.bcp.2011.04.002

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software